| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $116.4M | — | +31.9% |
| R&D Expense | $15.3M | — | +7.5% |
| SG&A Expense | $41.0M | — | +25.3% |
| Operating Income | $53.7M | — | +48.4% |
| Pre-tax Income | $61.4M | — | +40.9% |
| Income Tax | $5.5M | — | -29.9% |
| Net Income | $55.9M | — | +56.5% |
| EPS (Basic) | $1.91 | — | +54.0% |
| EPS (Diluted) | $1.83 | — | +52.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $501.3M | +1.0% | +62.4% |
| Accounts Receivable | $127.0M | -0.3% | +23.0% |
| Inventory | $42.6M | +5.4% | +42.4% |
| Current Assets | $1.02B | -0.5% | +33.0% |
| Total Assets | $1.40B | +4.7% | +30.0% |
| Current Liabilities | $107.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $80.4M | — | +159.6% |
| Capital Expenditures | $7.1M | — | +15.2% |
| Investing Cash Flow | -$63.6M | — | -16.1% |
| Financing Cash Flow | -$10.5M | — | +16.1% |
| Free Cash Flow | $73.2M | — | +195.7% |
| +35.6% |
| Total Liabilities | $120.2M | +5.3% | +34.0% |
| Stockholders' Equity | $1.28B | +4.7% | +29.7% |